Ceregene Expands Into New Facility
SAN DIEGO, April 18 /PRNewswire/ -- Ceregene, Inc., a biotechnology company focused on gene therapies for neurological disorders such as Alzheimer's disease and Parkinson's disease, announced today that it has moved into a newly constructed facility with approximately 20,000 square feet of laboratory and administrative space.
Located in the University Towne Centre area of San Diego, Ceregene's new facility is in close proximity to the University of California, San Diego, The Salk Institute for Biological Studies and many of San Diego's leading biotechnology companies and research institutions.
``Ceregene's new facility provides us with the latest in laboratory capabilities and room to grow as we accelerate our research and development programs,'' stated Jeffrey M. Ostrove, Ph.D., president and chief operating officer of Ceregene.
Ceregene's new address is: 9381 Judicial Drive, Suite 130, San Diego, CA 92121-3831.
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development and commercialization of gene therapies for neurological disorders including Alzheimer's disease and Parkinson's disease. Ceregene was launched in January 2001 and is a majority-owned subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE - news), which is headquartered in Foster City, CA.
Statements made herein about Ceregene and Cell Genesys, other than statements of historical fact, including statements about the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made including risks associated with the success of research and development programs, clinical trials, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Ceregene and Cell Genesys, please see the Cell Genesys Annual Report on Form 10-K dated April 1, 2002 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission.
SOURCE: Ceregene, Inc. |
